Patrys (ASX:PAB) has said anticancer candidate PAT-SM6 was found to be safe and potentially effective during a phase I/IIa trial in multiple myeloma. [ + ]

The persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI. [ + ]

Cogstate (ASX:CGS) will supply cognition tests for a phase III trial involving using Eli Lilly's anti-amyloid drug Solanezumab to slow the onset of Alzheimer's disease. [ + ]

Fio Corporation's Deki Reader - a mobile in vitro diagnostic device - has demonstrated consistent interpretation of rapid diagnostic tests (RDTs) for multiple malaria strains in a field evaluation. [ + ]

Researchers from the British Antarctic Survey and the University of Reading have demonstrated for the first time that after over 1500 years frozen in Antarctic ice, moss can come back to life and continue to grow. [ + ]

Researchers from the BICEP2 collaboration have announced the first direct evidence of cosmic inflation - the rapid expansion of the universe which immediately followed the Big Bang. Until now, the idea of this exponential expansion was just a theory. [ + ]

More than 80% of patients with cutaneous B-cell lymphoma enrolled in a phase II trial of Ascend's in-licensed cancer drug ASN-002 demonstrated a complete or partial response to treatment. [ + ]

The FDA has granted Cochlear (ASX:COH) approval to sell the Nucleus Hybrid L24 - a new cochlear implant system designed to address high-frequency hearing loss - in the US. [ + ]

Virax Holdings (ASX:VHL) has arranged to buy Pathway Oncology, a company with an exclusive licence to a cancer drug candidate due to enter phase II trials in breast cancer and multiple myeloma. [ + ]

Imugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx. [ + ]

Scientists from the UK and Australia have created a mouse strain that expresses a fluorescing biosensor in every cell of its body, allowing diseased cells and drugs to be tracked and evaluated in real time. [ + ]

IntegenX, a developer of rapid human DNA identification technology, has met the US FBI guidelines to upload directly to the National DNA Index System (NDIS) known arrestee and convicted offender DNA profiles, as well as casework known samples. The profiles will be generated with the RapidHIT System using Life Technologies GlobalFiler Express kits from Thermo Fisher Scientific. [ + ]

Mesoblast's (ASX:MSB) hiring of a former Novartis CFO so soon after former Roche executive William Burns joined its board may help the company pursue international partnership deals, Bell Potter said. [ + ]

Genetic Technologies (ASX:GTG) said economic modelling has shown the cost-effectiveness of using BREVAGen to help direct chemoprevention to women at elevated risk of breast cancer. [ + ]

Fibrotech said a phase Ia trial has demonstrated the safety of antifibrotic candidate FT011 in healthy volunteers, and revealed the company has started dosing for a phase IIb study. [ + ]